Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor (TERAVECT)

GERCOR - Multidisciplinary Oncology Cooperative Group

Status and phase

Terminated

Phase 3

Conditions

Liver Metastases

Resection

Metabolic Radiotherapy

Digestive Neuroendocrine Tumors

Treatments

Other: simple monitoring without active therapy

Drug: In111-Pentetréotide

Study type

Interventional

Funder types

Other

Identifiers

NCT02465112

TERAVECT D13-2

Details and patient eligibility

About

TERAVECT is a phase III randomized study of patients with digestive neuroendocrine tumors after complete surgical resection of liver metastases treated with In111-Pentetreotide-based adjuvant radiotherapy.

In this study, targeted radionuclide therapy is used at an earlier stage of the disease.The objective is to target residual tumor cells and/or micrometastases which escaped surgical resection. Given the poor prognosis associated with recurrence, this treatment should prevent relapse.

Enrollment

4 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Signed and dated informed consent,
Age ≥ 18 years,
Patients with well differenciated digestive neuroendocrine tumors and liver metastases, for whom a complete surgical resection of liver metastases and of the primary tumor was performed, in 1 or 2 times,
Immunohistochemical confirmation of neuroendocrine tumors with WHO 2010 grading specification and Ki67 determined of the surgical specimen,
ECOG Performance Status (PS) 0-1,
Adequate hematological status: Platelets >100000/mm3, Hemoglobin >10g/dL,
Adequate Clearance Creatinine >60 mL/min,
Adequate liver function: Total Serum Bilirubin <1.5x upper limit of normal (ULN), transaminases <3 x ULN,
Grade of In111-Pentetreotide uptake ≥ 2 (scored according to the Krenning et al scale.: more intense than physiological liver uptake),
Treatment started within 14 weeks after surgical resection,
Men and women are required to use adequate birth control measures during the course of the study and for a period of 12 months after the last administration of study drug. Female patients with childbearing potential must have a negative serum pregnant test (β-HCG) within 7 days before starting study treatment,
Life expectancy >6 months
Registration with the National Health Care System (CMU included for France)

Exclusion criteria

History of previous or second cancer or progressive cancer occurring within 5 years prior to inclusion, except for basal cell or squamous cell carcinoma,
Patients with known sensibility or hypersensibility to In111- Pentetreotide or any component of the treatment drug,
Pregnant or breast-feeding women without adequate birth control measures,
Patient with known medical history of psychological or psychiatric disorders that may affect patient participation in study due to lack of cooperation or loss of autonomy preventing hospitalization and initiation of study treatment (in good radiation protection conditions),
Treatment with any investigational drug within 28 days prior to study entry,
Patient protected by law (tutelage or guardianship).